(17-alpha)-19-Norpregna-1,3,5(10)-trien-20-yne-3,17,diol

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

33 Suppliers, 13 USDMF, 10 CEP/COS, 4 JDMF, 2 EU WC, 13 NDC API, 17 Listed Suppliers

DEVELOPMENTS

21 Drug(s) in Development

21 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

4 Suppliers

4 Suppliers

DOSSIERs // Finished Dosage Forms

709 Dossiers, 417 FDA Orange Book, 114 Europe, 88 Canada, 2 Australia, 47 South Africa, 41 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL-28 - 0.02MG;1MG, TABLET;ORAL-21 - 0.03MG;1.5MG, TABLET;ORAL-28 - 0.03MG;0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL-21 - 0.03MG;1.5MG, TABLET;ORAL-21 - 0.02MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL-28 - 0.035MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL-28 - 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG, TABLET;ORAL-28 - 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL-28 - 0.035MG;0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL-28 - 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL-21 - 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL-21 - 0.15MG;0.03MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 0.02MG;1MG, TABLET;ORAL - 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A, CAPSULE;ORAL - 0.02MG;1MG, TABLET, CHEWABLE, TABLET;ORAL - 0.01MG,0.01MG,N/A;1MG,N/A,N/A, TABLET;ORAL - 0.02MG;0.1MG, RING;VAGINAL - 0.013MG/24HR;0.15MG/24HR, TABLET;ORAL - 0.0025MG;0.5MG, TABLET;ORAL - 0.005MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL-28 - 0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG, FILM, EXTENDED RELEASE;TRANSDERMAL - 0.035MG/24HR;0.15MG/24HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, RING;VAGINAL - 0.015MG/24HR;0.12MG/24HR, TABLET;ORAL-28 - 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 0.035MG;0.4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 3MG;0.02MG, TABLET;ORAL - 0.02MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 0.01MG,0.01MG;1MG,N/A, TABLET, CHEWABLE;ORAL - 0.025MG;0.8MG

RELATED EXCIPIENT COMPANIES

Suppliers, 38 Kerry, 25 BASF, 23 Roquette, 14 Microlex e.U, 12 Sigachi Industries, 11 Corel Pharma Chem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 9 Gangwal Healthcare, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 8 Gangwal Chemicals, 7 Seppic, 7 DFE Pharma, 7 Ideal Cures Pvt Ltd, 6 Lonza Capsugel, 5 Actylis, 5 SPI Pharma, 5 Vasa Pharmachem, 4 Ingredion Pharma Solutions, 4 Prachin Chemical, 4 Nanjing Well Pharmaceutical, 3 Kima Chemical, 3 Pharmatrans-Sanaq, 3 Boai NKY Pharmaceuticals Ltd, 2 Nomisma Healthcare, 2 Rochem International Inc, 2 DKSH, 2 The Dow Chemical Company, 2 Seqens, 2 Ulanqab Kema New Material, 2 Clariant, 1 ACG Worldwide, 1 Pfanstiehl, 1 Doshion Polyscience, 1 Qualicaps, 1 Aeon Procare, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Finar, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Jai Radhe Sales

EXCIPIENTS BY APPLICATIONS

71 Fillers, Diluents & Binders, 53 Coating Systems & Additives, 34 Disintegrants & Superdisintegrants, 32 Direct Compression, 32 Controlled & Modified Release, 25 Granulation, 23 Thickeners and Stabilizers, 20 Lubricants & Glidants, 17 Taste Masking, 16 Solubilizers, 13 Co-Processed Excipients, 12 Topical, 10 Film Formers & Plasticizers, 9 Parenteral, 7 Chewable & Orodispersible Aids, 7 API Stability Enhancers, 5 Emulsifying Agents, 5 Rheology Modifiers, 5 Empty Capsules, 4 Vegetarian Capsules, 2 Surfactant & Foaming Agents, 2 Coloring Agents

GLOBAL SALES INFORMATION

452 US Medicaid Prescriptions, 98 Finished Drug Prices

MARKET PLACE

16 APIs, 3 DOSSIERS // FDF, 1 EXCIPIENTS, 2 CONTRACT SERVICES

PATENTS

30 US Patents, 5 Health Canada Patents

ANALYTICAL SOLUTION(s)

1 BioAnalytical Methods, 3 EDQM Standards, 3 USP Standards, 3 JP Standards, 3 Other Ref. Standards

DIGITAL CONTENT

6 Data Compilation & Company Tracker #PharmaFlow, 150 News

Annual Sales of (17-alpha)-19-Norpregna-1,3,5(10)-trien-20-yne-3,17,diol reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

(17-alpha)-19-Norpregna-1,3,5(10)-trien-20-yne-3,17,diol

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

33 Suppliers

13 USDMF

10 CEP/COS

4 JDMF

2 EU WC

13 NDC API

17 Listed Suppliers

DEVELOPMENTS

21 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Exports

FDF Imports

INTERMEDIATES

4 Suppliers

DOSSIERs // Finished Dosage Forms

709 Dossiers

417 FDA Orange Book

114 Europe

88 Canada

2 Australia

47 South Africa

41 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL-28 - 0.02MG;1MG

TABLET;ORAL-21 - 0.03MG;1.5MG

TABLET;ORAL-28 - 0.03MG;0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL-21 - 0.03MG;1.5MG

TABLET;ORAL-21 - 0.02MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL-28 - 0.035MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL-28 - 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG

TABLET;ORAL-28 - 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL-28 - 0.035MG;0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL-28 - 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL-21 - 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL-21 - 0.15MG;0.03MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 0.02MG;1MG

TABLET;ORAL - 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A

CAPSULE;ORAL - 0.02MG;1MG

TABLET, CHEWABLE, TABLET;ORAL - 0.01MG,0.01MG,N/A;1MG,N/A,N/A

TABLET;ORAL - 0.02MG;0.1MG

RING;VAGINAL - 0.013MG/24HR;0.15MG/24HR

TABLET;ORAL - 0.0025MG;0.5MG

TABLET;ORAL - 0.005MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL-28 - 0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG

FILM, EXTENDED RELEASE;TRANSDERMAL - 0.035MG/24HR;0.15MG/24HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RING;VAGINAL - 0.015MG/24HR;0.12MG/24HR

TABLET;ORAL-28 - 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 0.035MG;0.4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 3MG;0.02MG

TABLET;ORAL - 0.02MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 0.01MG,0.01MG;1MG,N/A

TABLET, CHEWABLE;ORAL - 0.025MG;0.8MG

RELATED EXCIPIENT COMPANIES

Suppliers

38 Kerry

25 BASF

23 Roquette

14 Microlex e.U

12 Sigachi Industries

11 Corel Pharma Chem

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

9 Gangwal Healthcare

8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

8 Gangwal Chemicals

7 Seppic

7 DFE Pharma

7 Ideal Cures Pvt Ltd

6 Lonza Capsugel

5 Actylis

5 SPI Pharma

5 Vasa Pharmachem

4 Ingredion Pharma Solutions

TABLET;ORAL-28 - 0.03MG;0.3MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL-21 - 0.02MG;1MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL-28 - 0.035MG;1MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL-28 - 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL-28 - 0.035MG;0.25MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL-28 - 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL-21 - 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL-21 - 0.15MG;0.03MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 0.005MG;1MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 0.035MG/24HR;0.15MG/24HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL-28 - 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 0.035MG;0.4MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 0.02MG;1MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons